Nature Communications (Aug 2024)
Mutant huntingtin impairs neurodevelopment in human brain organoids through CHCHD2-mediated neurometabolic failure
- Pawel Lisowski,
- Selene Lickfett,
- Agnieszka Rybak-Wolf,
- Carmen Menacho,
- Stephanie Le,
- Tancredi Massimo Pentimalli,
- Sofia Notopoulou,
- Werner Dykstra,
- Daniel Oehler,
- Sandra López-Calcerrada,
- Barbara Mlody,
- Maximilian Otto,
- Haijia Wu,
- Yasmin Richter,
- Philipp Roth,
- Ruchika Anand,
- Linda A. M. Kulka,
- David Meierhofer,
- Petar Glazar,
- Ivano Legnini,
- Narasimha Swamy Telugu,
- Tobias Hahn,
- Nancy Neuendorf,
- Duncan C. Miller,
- Annett Böddrich,
- Amin Polzin,
- Ertan Mayatepek,
- Sebastian Diecke,
- Heidi Olzscha,
- Janine Kirstein,
- Cristina Ugalde,
- Spyros Petrakis,
- Sidney Cambridge,
- Nikolaus Rajewsky,
- Ralf Kühn,
- Erich E. Wanker,
- Josef Priller,
- Jakob J. Metzger,
- Alessandro Prigione
Affiliations
- Pawel Lisowski
- Quantitative Stem Cell Biology, Berlin Institute for Medical Systems Biology (BIMSB)
- Selene Lickfett
- Faculty of Mathematics and Natural Sciences, Heinrich Heine University
- Agnieszka Rybak-Wolf
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Carmen Menacho
- Faculty of Mathematics and Natural Sciences, Heinrich Heine University
- Stephanie Le
- Faculty of Mathematics and Natural Sciences, Heinrich Heine University
- Tancredi Massimo Pentimalli
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Sofia Notopoulou
- Institute of Applied Biosciences (INAB), Centre For Research and Technology Hellas (CERTH)
- Werner Dykstra
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Daniel Oehler
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty and University Hospital Düsseldorf, Cardiovascular Research Institute Düsseldorf (CARID)
- Sandra López-Calcerrada
- Instituto de Investigación Hospital 12 de Octubre (i + 12)
- Barbara Mlody
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Maximilian Otto
- Quantitative Stem Cell Biology, Berlin Institute for Medical Systems Biology (BIMSB)
- Haijia Wu
- Institute of Molecular Medicine, Medical School
- Yasmin Richter
- Cell Biology, University of Bremen
- Philipp Roth
- Quantitative Stem Cell Biology, Berlin Institute for Medical Systems Biology (BIMSB)
- Ruchika Anand
- Institute of Biochemistry and Molecular Biology I, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University
- Linda A. M. Kulka
- Institute of Physiological Chemistry, Martin-Luther-University
- David Meierhofer
- Quantitative RNA Biology, Max Planck Institute for Molecular Genetics
- Petar Glazar
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Ivano Legnini
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Narasimha Swamy Telugu
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Tobias Hahn
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Nancy Neuendorf
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Duncan C. Miller
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Annett Böddrich
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Amin Polzin
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty and University Hospital Düsseldorf, Cardiovascular Research Institute Düsseldorf (CARID)
- Ertan Mayatepek
- Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital Düsseldorf, Heinrich Heine University
- Sebastian Diecke
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Heidi Olzscha
- Institute of Molecular Medicine, Medical School
- Janine Kirstein
- Cell Biology, University of Bremen
- Cristina Ugalde
- Instituto de Investigación Hospital 12 de Octubre (i + 12)
- Spyros Petrakis
- Institute of Applied Biosciences (INAB), Centre For Research and Technology Hellas (CERTH)
- Sidney Cambridge
- Institute of Anatomy II, Heinrich-Heine-University
- Nikolaus Rajewsky
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Ralf Kühn
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Erich E. Wanker
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Josef Priller
- Department of Psychiatry and Psychotherapy, Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité – Universitätsmedizin
- Jakob J. Metzger
- Quantitative Stem Cell Biology, Berlin Institute for Medical Systems Biology (BIMSB)
- Alessandro Prigione
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- DOI
- https://doi.org/10.1038/s41467-024-51216-w
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 27
Abstract
Abstract Expansion of the glutamine tract (poly-Q) in the protein huntingtin (HTT) causes the neurodegenerative disorder Huntington’s disease (HD). Emerging evidence suggests that mutant HTT (mHTT) disrupts brain development. To gain mechanistic insights into the neurodevelopmental impact of human mHTT, we engineered male induced pluripotent stem cells to introduce a biallelic or monoallelic mutant 70Q expansion or to remove the poly-Q tract of HTT. The introduction of a 70Q mutation caused aberrant development of cerebral organoids with loss of neural progenitor organization. The early neurodevelopmental signature of mHTT highlighted the dysregulation of the protein coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2), a transcription factor involved in mitochondrial integrated stress response. CHCHD2 repression was associated with abnormal mitochondrial morpho-dynamics that was reverted upon overexpression of CHCHD2. Removing the poly-Q tract from HTT normalized CHCHD2 levels and corrected key mitochondrial defects. Hence, mHTT-mediated disruption of human neurodevelopment is paralleled by aberrant neurometabolic programming mediated by dysregulation of CHCHD2, which could then serve as an early interventional target for HD.